iOmx – Developing novel checkpoint modulators to treat solid tumors
iOmx is perfectly positioned to develop a broad pipeline of novel immunotherapies for treating cancers that are not responsive to conventional checkpoint inhibitors.
Using a systematic, high-throughput target discovery approach, iOTarg, iOmx is aiming to unveil evasion/resistance strategies used by cancer cells against immune attack in order to develop next-generation targeted cancer immunotherapies. To date, iOmx has identified over 100 novel targets and valdiated the inhibtion of many of these targets to result in stronger anti-tumor activity over the well-characterized and commercialized checkpoint pathways, including the PD-1/PD-L1 axis.
Industry
Therapeutics
